IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives

Sho Torii, Frank D Kolodgie, Renu Virmani, Aloke V Finn Cardiovascular Pathology, CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Endovascular therapy has evolved as a main treatment option especially in patients with short (<25 cm) femoropopliteal lesion. The latest...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Torii S, Kolodgie FD, Virmani R, Finn AV
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2019
Materias:	Drug Coated Balloon Superficial Femoral Artery Percutaneous Transluminal Angioplasty Peripheral Artery Disease Endovascular therapy IN.PACT Medical technology R855-855.5
Acceso en línea:	https://doaj.org/article/aac9ad146ef5438bb3be7ad70fa99a5f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aac9ad146ef5438bb3be7ad70fa99a5f
record_format	dspace
spelling	oai:doaj.org-article:aac9ad146ef5438bb3be7ad70fa99a5f2021-12-02T07:19:12ZIN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives1179-1470https://doaj.org/article/aac9ad146ef5438bb3be7ad70fa99a5f2019-02-01T00:00:00Zhttps://www.dovepress.com/inpacttm-admiraltm-drug-coated-balloons-in-peripheral-artery-disease-c-peer-reviewed-article-MDERhttps://doaj.org/toc/1179-1470Sho Torii, Frank D Kolodgie, Renu Virmani, Aloke V Finn Cardiovascular Pathology, CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Endovascular therapy has evolved as a main treatment option especially in patients with short (<25 cm) femoropopliteal lesion. The latest guideline recommends the use of drugeluting devices (both drug-coated balloons [DCBs] and drug-eluting stents) in short femoropopliteal esions as class IIb recommendation. DCB usage is also recommended for in-stent restenosis lesions (class IIb). DCBs are a more attractive treatment option because the lack of metal prosthesis allows for more flexibility in future treatment options including the option of treating nonstenting zones, previously DCB-treated zones with DCBs again. The IN.PACT™ Admiral™ DCB has shown promising clinical performance in several randomized control trials and global registries, and is currently the market DCB leader for the treatment of femoropopliteal lesions with more than 200,000 patients treated thus far. Currently, more than 10 DCBs have received Conformité Européene mark for the treatment of femoropopliteal atherosclerotic disease. Three of these (including IN.PACT Admiral DCBs) have also received Food and Drug Administration approval in the USA. However, some Conformité Européene-marked DCBs have failed to show consistent results in their clinical studies suggesting all DCBs are not created equal. Each DCB is unique (ie, drug type, drug dose, crystallinity, and excipient) with different clinical outcomes. In the current review, we will focus on the preclinical and clinical results of not only IN.PACT Admiral DCB, but also the other currently available DCBs. Keywords: drug-coated balloon, superficial femoral artery, percutaneous transluminal angioplasty, peripheral artery disease, drug-eluting stent, critical limb ischemiaTorii SKolodgie FDVirmani RFinn AVDove Medical PressarticleDrug Coated BalloonSuperficial Femoral ArteryPercutaneous Transluminal AngioplastyPeripheral Artery DiseaseEndovascular therapyIN.PACTMedical technologyR855-855.5ENMedical Devices: Evidence and Research, Vol Volume 12, Pp 53-64 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Drug Coated Balloon Superficial Femoral Artery Percutaneous Transluminal Angioplasty Peripheral Artery Disease Endovascular therapy IN.PACT Medical technology R855-855.5
spellingShingle	Drug Coated Balloon Superficial Femoral Artery Percutaneous Transluminal Angioplasty Peripheral Artery Disease Endovascular therapy IN.PACT Medical technology R855-855.5 Torii S Kolodgie FD Virmani R Finn AV IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives
description	Sho Torii, Frank D Kolodgie, Renu Virmani, Aloke V Finn Cardiovascular Pathology, CVPath Institute, Inc., Gaithersburg, MD, USA Abstract: Endovascular therapy has evolved as a main treatment option especially in patients with short (<25 cm) femoropopliteal lesion. The latest guideline recommends the use of drugeluting devices (both drug-coated balloons [DCBs] and drug-eluting stents) in short femoropopliteal esions as class IIb recommendation. DCB usage is also recommended for in-stent restenosis lesions (class IIb). DCBs are a more attractive treatment option because the lack of metal prosthesis allows for more flexibility in future treatment options including the option of treating nonstenting zones, previously DCB-treated zones with DCBs again. The IN.PACT™ Admiral™ DCB has shown promising clinical performance in several randomized control trials and global registries, and is currently the market DCB leader for the treatment of femoropopliteal lesions with more than 200,000 patients treated thus far. Currently, more than 10 DCBs have received Conformité Européene mark for the treatment of femoropopliteal atherosclerotic disease. Three of these (including IN.PACT Admiral DCBs) have also received Food and Drug Administration approval in the USA. However, some Conformité Européene-marked DCBs have failed to show consistent results in their clinical studies suggesting all DCBs are not created equal. Each DCB is unique (ie, drug type, drug dose, crystallinity, and excipient) with different clinical outcomes. In the current review, we will focus on the preclinical and clinical results of not only IN.PACT Admiral DCB, but also the other currently available DCBs. Keywords: drug-coated balloon, superficial femoral artery, percutaneous transluminal angioplasty, peripheral artery disease, drug-eluting stent, critical limb ischemia
format	article
author	Torii S Kolodgie FD Virmani R Finn AV
author_facet	Torii S Kolodgie FD Virmani R Finn AV
author_sort	Torii S
title	IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives
title_short	IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives
title_full	IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives
title_fullStr	IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives
title_full_unstemmed	IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives
title_sort	in.pacttm admiraltm drug-coated balloons in peripheral artery disease: current perspectives
publisher	Dove Medical Press
publishDate	2019
url	https://doaj.org/article/aac9ad146ef5438bb3be7ad70fa99a5f
work_keys_str_mv	AT toriis inpacttmadmiraltmdrugcoatedballoonsinperipheralarterydiseasecurrentperspectives AT kolodgiefd inpacttmadmiraltmdrugcoatedballoonsinperipheralarterydiseasecurrentperspectives AT virmanir inpacttmadmiraltmdrugcoatedballoonsinperipheralarterydiseasecurrentperspectives AT finnav inpacttmadmiraltmdrugcoatedballoonsinperipheralarterydiseasecurrentperspectives
_version_	1718399470892220416

IN.PACTTM AdmiralTM drug-coated balloons in peripheral artery disease: current perspectives

Ejemplares similares